<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528319</url>
  </required_header>
  <id_info>
    <org_study_id>MG-1</org_study_id>
    <nct_id>NCT01528319</nct_id>
  </id_info>
  <brief_title>Open-Label Study for Shoulder Dislocation Using MG-1</brief_title>
  <acronym>MG-1</acronym>
  <official_title>Open Clinical Trial of Arthroscopic Bankart Repair Using MG-1 for Dislocation of the Shoulder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson K.K. Medical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson K.K. Medical Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of arthroscopic Bankart repair using MG-1 for dislocation
      of shoulder
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgery Success</measure>
    <time_frame>12 weeks after surgery</time_frame>
    <description>The rate of successful cases when surgery success is defined as &quot;Procedure success is confirmed, the anchors are confirmed to be in the burr holes by the MRI examination, the glenohumeral ligament labral complex is maintained at the anterior edge of the glenoid cavity at 12 weeks after surgery, and there is no need of retreatment&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Function Evaluation</measure>
    <time_frame>12 weeks</time_frame>
    <description>To evaluate the Japan Shoulder Society Shoulder Instability Score (JSS-SIS) and Rowe Score at 12 weeks after surgery
JSS-SIS Score (subscales are summed, higher values represent a better outcome):
Pain (0 to 20)
Function (0 to 20)
Range of Motion (0 to 20)
Evaluation of X-ray findings (0 to 10)
Stability (0 to 30)
Rowe Score (subscales are summed, higher values represent a better outcome):
Stability (0 to 50)
Motion (0 to 20)
Function (0 to 30)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>12 weeks</time_frame>
    <description>The rate of successful cases when procedure success was defined as &quot;The anchors can be inserted into the burr holes without breakage and the glenohumeral ligament labral complex can be sutured without tear of the sutures&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Function Evaluation</measure>
    <time_frame>24 weeks</time_frame>
    <description>To evaluate the JSS-SIS score and Rowe score at 24 weeks after surgery
JSS-SIS Score (subscales are summed, higher values represent a better outcome):
Pain (0 to 20)
Function (0 to 20)
Range of Motion (0 to 20)
Evaluation of X-ray findings (0 to 10)
Stability (0 to 30)
Rowe Score (subscales are summed, higher values represent a better outcome):
Stability (0 to 50)
Motion (0 to 20)
Function (0 to 30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Changes in One or More Laboratory Tests</measure>
    <time_frame>12 weeks and 24 weeks after surgery</time_frame>
    <description>To evaluate changes over time in each laboratory test item from before surgery to 12 and 24 weeks after surgery regarding the presence or absence of abnormal changes, causal relationship with this product and causes for development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Evaluation</measure>
    <time_frame>Between the time of obtainment of consent and 24 weeks after surgery</time_frame>
    <description>To evaluate all undesirable events which occurred between the time of obtainment of consent and 24 weeks after surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Shoulder Dislocation</condition>
  <arm_group>
    <arm_group_label>MG-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MG-1</intervention_name>
    <description>Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.</description>
    <arm_group_label>MG-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with dislocation of the shoulder and indicated for arthroscopic Bankart
             repair

          -  Patients of 16 years or older

          -  Patients who understand the contents of the study and from whom a written consent can
             be obtained

          -  Patients who can visit the hospital for follow-ups after surgery

        Exclusion Criteria:

          -  Patients with serious complications

          -  Patients with comminuted fracture which may prevent fixation of the anchors

          -  Patients with the following diseases or conditions which may delay healing

               1. Lack of blood, infection, etc.

               2. Psychiatric disorder, alcohol poisoning, drug toxicity, etc.

               3. Tissues around the surgical site are not healthy under steroid therapy or
                  chemotherapy

          -  Patients with epilepsy or bone disease (cystic change, osteopenia, etc.)

          -  Patients with dementia

          -  Patients with a history of allergy to glycolic acid, poly-L-lactic acid, Î²-tricalcium
             phosphate, polyethylene or polydioxane

          -  Patients who cannot undergo general anesthesia

          -  Patients who cannot undergo plain X-ray examination or MRI examination

          -  Patients with previous bone grafting in the shoulder joint

          -  Patients who participated in another clinical trial within past 3 months

          -  Patients who are pregnant or lactating. Patients who plan to be pregnant within a year

          -  Patients judged to be inappropriate for the study by the (sub)investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroyuki Sugaya, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Funabashi Orthopaedic Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Funabashi-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <results_first_submitted>January 26, 2014</results_first_submitted>
  <results_first_submitted_qc>July 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2014</results_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthroscopic Bankart repair</keyword>
  <keyword>Suture anchor</keyword>
  <keyword>Shoulder dislocation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Dislocations</mesh_term>
    <mesh_term>Shoulder Dislocation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MG-1</title>
          <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Weeks After Surgery</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MG-1</title>
          <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Surgery Success</title>
        <description>The rate of successful cases when surgery success is defined as âProcedure success is confirmed, the anchors are confirmed to be in the burr holes by the MRI examination, the glenohumeral ligament labral complex is maintained at the anterior edge of the glenoid cavity at 12 weeks after surgery, and there is no need of retreatmentâ</description>
        <time_frame>12 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MG-1</title>
            <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
          </group>
        </group_list>
        <measure>
          <title>Surgery Success</title>
          <description>The rate of successful cases when surgery success is defined as âProcedure success is confirmed, the anchors are confirmed to be in the burr holes by the MRI examination, the glenohumeral ligament labral complex is maintained at the anterior edge of the glenoid cavity at 12 weeks after surgery, and there is no need of retreatmentâ</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Function Evaluation</title>
        <description>To evaluate the Japan Shoulder Society Shoulder Instability Score (JSS-SIS) and Rowe Score at 12 weeks after surgery
JSS-SIS Score (subscales are summed, higher values represent a better outcome):
Pain (0 to 20)
Function (0 to 20)
Range of Motion (0 to 20)
Evaluation of X-ray findings (0 to 10)
Stability (0 to 30)
Rowe Score (subscales are summed, higher values represent a better outcome):
Stability (0 to 50)
Motion (0 to 20)
Function (0 to 30)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MG-1</title>
            <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Function Evaluation</title>
          <description>To evaluate the Japan Shoulder Society Shoulder Instability Score (JSS-SIS) and Rowe Score at 12 weeks after surgery
JSS-SIS Score (subscales are summed, higher values represent a better outcome):
Pain (0 to 20)
Function (0 to 20)
Range of Motion (0 to 20)
Evaluation of X-ray findings (0 to 10)
Stability (0 to 30)
Rowe Score (subscales are summed, higher values represent a better outcome):
Stability (0 to 50)
Motion (0 to 20)
Function (0 to 30)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The JSS-SIS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The Rowe score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success</title>
        <description>The rate of successful cases when procedure success was defined as âThe anchors can be inserted into the burr holes without breakage and the glenohumeral ligament labral complex can be sutured without tear of the suturesâ</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MG-1</title>
            <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Success</title>
          <description>The rate of successful cases when procedure success was defined as âThe anchors can be inserted into the burr holes without breakage and the glenohumeral ligament labral complex can be sutured without tear of the suturesâ</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Function Evaluation</title>
        <description>To evaluate the JSS-SIS score and Rowe score at 24 weeks after surgery
JSS-SIS Score (subscales are summed, higher values represent a better outcome):
Pain (0 to 20)
Function (0 to 20)
Range of Motion (0 to 20)
Evaluation of X-ray findings (0 to 10)
Stability (0 to 30)
Rowe Score (subscales are summed, higher values represent a better outcome):
Stability (0 to 50)
Motion (0 to 20)
Function (0 to 30)</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MG-1</title>
            <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Function Evaluation</title>
          <description>To evaluate the JSS-SIS score and Rowe score at 24 weeks after surgery
JSS-SIS Score (subscales are summed, higher values represent a better outcome):
Pain (0 to 20)
Function (0 to 20)
Range of Motion (0 to 20)
Evaluation of X-ray findings (0 to 10)
Stability (0 to 30)
Rowe Score (subscales are summed, higher values represent a better outcome):
Stability (0 to 50)
Motion (0 to 20)
Function (0 to 30)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>The JSS-SIS score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>The Rowe score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Changes in One or More Laboratory Tests</title>
        <description>To evaluate changes over time in each laboratory test item from before surgery to 12 and 24 weeks after surgery regarding the presence or absence of abnormal changes, causal relationship with this product and causes for development</description>
        <time_frame>12 weeks and 24 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MG-1</title>
            <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Changes in One or More Laboratory Tests</title>
          <description>To evaluate changes over time in each laboratory test item from before surgery to 12 and 24 weeks after surgery regarding the presence or absence of abnormal changes, causal relationship with this product and causes for development</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event Evaluation</title>
        <description>To evaluate all undesirable events which occurred between the time of obtainment of consent and 24 weeks after surgery</description>
        <time_frame>Between the time of obtainment of consent and 24 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MG-1</title>
            <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event Evaluation</title>
          <description>To evaluate all undesirable events which occurred between the time of obtainment of consent and 24 weeks after surgery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MG-1</title>
          <description>Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyogenic arthritis involving shoulder region</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Department Chief, Clinical Development &amp; PMS</name_or_title>
      <organization>Johnson &amp; Johnson K.K. Medical Company</organization>
      <phone>+81-3-4411-6789</phone>
      <email>yikeda5@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

